- Home
- TRVI vs ETON Comparison
TRVI vs ETON Comparison
Compare TRVI & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- ETON
- Stock Information
- Founded
- TRVI 2011
- ETON 2017
- Country
- TRVI United States
- ETON United States
- Employees
- TRVI N/A
- ETON N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- ETON Health Care
- Exchange
- TRVI Nasdaq
- ETON Nasdaq
- Market Cap
- TRVI 211.4M
- ETON 199.5M
- IPO Year
- TRVI 2019
- ETON 2018
- Fundamental
- Price
- TRVI $2.75
- ETON $10.02
- Analyst Decision
- TRVI Strong Buy
- ETON Strong Buy
- Analyst Count
- TRVI 8
- ETON 3
- Target Price
- TRVI $9.13
- ETON $12.00
- AVG Volume (30 Days)
- TRVI 659.5K
- ETON 212.9K
- Earning Date
- TRVI 11-06-2024
- ETON 11-12-2024
- Dividend Yield
- TRVI N/A
- ETON N/A
- EPS Growth
- TRVI N/A
- ETON N/A
- EPS
- TRVI N/A
- ETON N/A
- Revenue
- TRVI N/A
- ETON $34,677,000.00
- Revenue This Year
- TRVI N/A
- ETON $19.61
- Revenue Next Year
- TRVI N/A
- ETON $82.71
- P/E Ratio
- TRVI N/A
- ETON N/A
- Revenue Growth
- TRVI N/A
- ETON 5.64
- 52 Week Low
- TRVI $0.97
- ETON $3.03
- 52 Week High
- TRVI $4.00
- ETON $11.11
- Technical
- Relative Strength Index (RSI)
- TRVI 37.52
- ETON 67.30
- Support Level
- TRVI $2.80
- ETON $8.76
- Resistance Level
- TRVI $3.22
- ETON $11.11
- Average True Range (ATR)
- TRVI 0.20
- ETON 0.66
- MACD
- TRVI -0.03
- ETON 0.10
- Stochastic Oscillator
- TRVI 14.68
- ETON 62.02
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.